Dr. Visanji completed her PhD in Pharmacology at Kings College London (UK) in 2004 then relocated to Canada, where she holds appointments at both the University of Toronto Department of Laboratory Medicine and Pathobiology and the Edmond J. Safra Program in Parkinson's Disease at Toronto Western Hospital. Dr. Visanji’s research focuses on the use of postmortem human tissues and pre-clinical models to probe the pathobiology of alpha-synuclein in Parkinson’s disease. In addition, she has an interest in the detection of peripheral alpha-synuclein as a biomarker and was a site co-investigator for the Michael J. Fox Foundation-sponsored Systemic Synuclein Sampling Study (S4). Dr. Visanji has published over 50 peer-reviewed publications in the field of Parkinson’s disease research and drug development. She is also a senior scientist at Rosetta Therapeutics, a University of Toronto/MaRS Innovation UTEST startup developing new molecular matter as leads for the cure of neurodegenerative diseases.